David Hua joins us and shares how regulations have changed medical cannabis: "Getting a medical card or recommendation wasn't too difficult in Prop 215, and was great as you got your recommendation, you could use it at any medical shop. But starting in 2018 if you had a recommendation, it didn't give you many benefits. You had to go to the state to get an official card in order to get taxes or the state taxes exempt."
Debby Goldsberry joins us and shares her concerns over new regulations on the California Cannabis Industry: "This is prohibition 2.0. It's a regulated market that's designed to keep most people out of the regulated market, and put cannabis into the hands of fewer and fewer people. I think there has been a lot of lobbying done at the legislature here in California by big business trying to keep cannabis in their hands."
Julianna Carella returns and shares how Treaibles is handling FDA regulations: "It's more important to keep the product on the shelf because now we have a situation where animals are relying on it, and last thing we want is for regulators to be confused about it and then pull the product."
Chuck Smith joins us and shares the potential of the States Act and its effect on the industry: "I think for the country to say, 'Look, these are legitimate business people. They're creating hundreds of thousands of jobs and creating a billion dollars worth of tax revenue. We need to treat them like any other industry.' That's what the States Act is all about. Now, we're going to do everything we can to support it."
The Phaxia on investment opportunity: "This is a fantastic period of time for investing in the space. Canada has not waited. They have war chests on their balance sheet of cash, not really much more they can build out in their market, so they're eyeing other opportunities. The US is a huge opportunity set for them. They're coming."
Dadi Segal from Panaxia explains the processes and equipment that go into producing pharmaceutical cannabis: "Regular analytical systems allow you to see cannabinoids to the milligram level. This machine allows you to see to the nanogram levels, now that allows you to do two things. One of them is detect the levels of cannabinoids in the blood stream, and it's very important for us once we go for clinical trials. For us as a pharmaceutical company, a clinical trial can never be subjective. It has to take the measurements of the cannabinoids in the blood stream, and check pharmacokinetics."
John Fowler helps us to manage expectations and think positively on the future of the Legal Cannabis Market: "We had an election over the summer, and our new Premier decided that it was better to allow small or medium-sized businesses access to the market. What does that mean? We're not going to have stores until April. In the short term, it doesn't look great. But in the long run, that means for the next 100 years after April, we get that private retail and I think that's pretty exciting."